Immune attack: The role of inflammation in Alzheimer disease

Nature Reviews Neuroscience

Volumn 16, Issue 6, 2015, Pages 358-372

  Heppner, Frank L ^a   Ransohoff, Richard M ^b   Becher, Burkhard ^c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b BIOGEN   (United States)

^c UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN;

ADAPTIVE IMMUNITY; ALZHEIMER DISEASE; ASTROCYTE; AUTOIMMUNITY; BONE MARROW CELL; DEGENERATIVE DISEASE; GENETIC ASSOCIATION; HUMAN; INNATE IMMUNITY; MACROGLIA; MICROGLIA; MULTIPLE SCLEROSIS; NERVE CELL DIFFERENTIATION; NERVE CELL MEMBRANE; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PHAGOCYTOSIS; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; ANIMAL; IMMUNOLOGY; INFLAMMATION; PATHOLOGY;

ALZHEIMER DISEASE; ANIMALS; HUMANS; INFLAMMATION;

EID: 84929921146     PISSN: 1471003X     EISSN: 14710048     Source Type: Journal    
DOI: 10.1038/nrn3880     Document Type: Review

References (217)

1. Wimo, A. & Prince, M. World Alzheimer Report 2010: The Global Economic Impact of Dementia (Alzheimer's Disease International (ADI), 2010).
2. Querfurth, H. W. & LaFerla, F. M. Alzheimer's disease. N. Engl. J. Med. 362, 329-344 (2010).
3. Hardy, J. & Selkoe, D. J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356 (2002).
4. Prokop, S., Miller, K. R. & Heppner, F. L. Microglia actions in Alzheimer's disease. Acta Neuropathol. 126, 461-477 (2013).
5. Gan dy, S. & Heppner, F. L. Microglia as dynamic and essential components of the amyloid hypothesis. Neuron 78, 575-577 (2013).
6. Perry, V. H. & Holmes, C. Microglial priming in neur odegenerative disease. Nature Rev. Neurol. 10, 217-224 (2014).
7. Cunningham, C. Microglia and neurodegeneration: the role of systemic inflammation. Glia 61, 71-90 (2013).
8. Sudduth, T. L., Schmitt, F. A., Nelson, P. T. & Wilcock, D. M. Neuroinflammatory phenotype in early Alzheimer's disease. Neurobiol. Aging 34, 1051-1059 (2013).
9. Krstic, D. & Knuesel, I. Deciphering the mechanism underlying late-onset Alzheimer disease. Nature Rev. Neurol. 9, 25-34 (2013).
10. Hickman, S. E. & El Khoury, J. TREM2 and the ne uroimmunology of Alzheimer's disease. Biochem. Pharmacol. 88, 495-498 (2014).
11. Heneka, M. T., Kummer, M. P. & Latz, E. Innate immune activation in neurodegenerative disease. Nature Rev. Immu nol. 14, 463-477 (2014).
12. Akiyama, H. et al. Inflammation and Alzheimer's disease. Neurobiol. Aging 21, 383-421 (2000).
13. Jonsson, T. et al. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 488, 96-99 (2012).
14. Scheuner, D. et al. Secreted amyloid ?-protein similar to that in the senile p laques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nature Med. 2, 864-870 (1996).
15. LaFerla, F. M. & Green, K. N. Animal models of Alzheimer disease. Cold Spring Harb. Perspect. Med. 2, a006320 (2012).
16. Haass, C., Kaether, C., Thinakaran, G. & Sisodia, S. Trafficking and proteolytic processing of APP. Cold Spring Harb. Perspect. Med. 2, a006270 (2012).
17. Holmes, C. et al. Long-term effects of A?42 immunisation in Alzheimer's disease: follow-up of a rando mised, placebo-controlled phase I trial. Lancet 372, 216-223 (2008).
18. Giacobini, E. & Gold, G. Alzheimer disease therapy-moving from amyloid-? to tau. Nature Rev. Neurol. 9, 677-686 (2013).
19. Wyss-Coray, T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nature Med. 12, 1005-1015 (2006).
20. Zhang, B. et al. Int egrated systems approach identifies genetic nodes and networks in late-onset Alzheimer's disease. Cell 153, 707-720 (2013).
21. Jonsson, T. et al. Variant of TREM2 associated with the risk of Alzh eimer's disease. N. Engl. J. Med. 368, 107-116 (2013).
22. Guerreiro, R. et al. TREM2 variants in Alzheimer's disease. N. Engl. J. Med. 368, 117-127 (2013). These two back-to-bac k studies identified rare variants of a single myeloid cell receptor as conferring surprisingly high risk for late-onset sporadic AD.
23. Bradshaw, E. M. et al. CD33 Alzheimer's disease locus: altered monocyte function and a myloid biology. Nature Neurosci. 16, 848-850 (2013).
24. Tarkowski, E., Andreasen, N., Tarkowski, A. & Blennow, K. Intrathecal inflammation precedes development of Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 74, 1200-1205 (2003).
25. Brosseron, F., Krauthausen, M., Kummer, M. & Henek a, M. T. Body fluid cytokine levels in mild cognitive impairment and Alzheimer's disease: a comparative overview. Mol. Neurobiol. 50, 534-544 (2014).
26. Krstic, D. et al. Systemic immune challeng es trigger and drive Alzheimer-like neuropathology in mice. J. Neuroinflamm. 9, 151 (2012).
27. Perry, V. H. Contribution of systemic inflammation to chronic neurodegeneration. Acta Neuropathol. 1 20, 277-286 (2010).
28. Cunningham, C. et al. Systemic inflammation induces acute behavioral and cognitive changes and accelerates neurodegenerative disease. Biol. Psychiatry 65, 304-312 (2009).
29. Holmes, C. et al. Systemic inflammation and disease progression in Alzheimer disease. Neurology 73, 768-774 (2009).
30. Cribbs, D. H. et al. Extensive innate immune gene activation accompanies brain aging, increasing vulnerability to cognitive decline and neurodegeneration: a microarray study. J. Neuroinflamm. 9, 179 (2012 ).
31. Schwartz, M. & Shechter, R. Systemic inflammatory cells fight off neurodegenerative disease. Nature Rev. Neurol. 6, 405-410 (2010).
32. Kyrkanides, S. et al. O steoarthritis accelerates and exacerbates Alzheimer's disease pathology in mice. J. Neuroinflamm. 8, 112 (2011).
33. Abuabara, K. et al. Cause-specific mortality in patients with severe psoriasis: a pop ulation-based cohort study in the U.K. Br. J. Dermatol. 163, 586-592 (2010).
34. Gisondi, P. et al. Mild cognitive impairment in patients with moderate to severe chronic plaque psoriasis. Dermatol ogy 228, 78-85 (2014).
35. Thaler, J. P. et al. Obesity is associated with hypothalamic injury in rodents and humans. J. Clin. Invest. 122, 153-162 (2012).
36. Takeda, S. et al. Diabetes-Accelerated memory dysfunction via cerebrovascular inflammation and A? deposition in an Alzheimer mouse model with diabetes. Proc. Natl Acad. Sci. USA 107, 7036-7041 (2010).
37. Mayeux R.,et al Genetic susceptibility and head injury as risk factors for Alzheimer's disease among community-dwelling elderly persons and their first-degree relatives. Ann. Neurol. 33, 494-501, 1993).
38. Heneka M. T.,et al. Locus ceruleus degeneration promotes Alzheimer pathogenesis in amyloid precursor protein 23 transgenic mice J. Neurosci. 26 1343-1354 2006).
39. Rubartelli, A. & Lotze, M. T. Inside, outside, upside down: damage-Associated molecular-pattern molecules (DAMPs) and redox. Trends Immunol. 28, 429-436 (2007).
40. Bornemann, K. D. et al. A?-induced inflammatory p rocesses in microglia cells of APP23 transgenic mice. Am. J. Pathol. 158, 63-73 (2001).
41. Stalder, A. K. et al. Invasion of hematopoietic cells into the brain of amyloid precursor protein transgenic mice. J. Neurosci. 25, 11125-11132 (2005).
42. Eikelenboom, P. et al. Neuroinflammation in Alzheimer's disease and prion disease. Glia 40, 232-239 (2002).
43. Streit, W. J. Microglia and Alzheimer's disease pathogenesis. J. Neurosci. Res. 77 1-8, 2004).
44. Prinz, M., Priller, J., Sisodia, S. S. & Ransohoff, R. M. Heterogeneity of CNS myeloid cells and their roles in neurodegeneration. Nature Neurosci. 14, 1227-1235 (2011).
45. International Multiple Sclerosis Genetics Consortium et al. Genetic risk and a primary role for cell-mediated im mune mechanisms in multiple sclerosis. Nature 476, 214-219 (2011).
46. Naj, A. C. et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nature Genet. 43, 436-441 (2011).
47. Thambisetty, M. et al. Effect of complement CR1 on brain amyloid burden during aging and its modification by APOE genotype. Biol. Psychiatry 73, 422-428 (2013).
48. Lambert, J. C. et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nature Genet. 41, 1094-1099 (2009).
49. Hollingworth P.,et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease Nature Genet. 43, 429-435, 2011).
50. Liang, Y. & Tedder, T. F. Identification of a CD20-, Fc?RI?-, and HTm4-related gene family: sixteen new MS4A family members expressed in human and mouse. Genomics 72, 119-127 (2001).
51. Ransohoff, R. M. A nimal models of multiple sclerosis: the good, the bad and the bottom line. Nature Neurosci. 15, 1074-1077 (2012).
52. Raj, T. et al. Polarization of the effects of autoimmune and neurodegenerative risk alleles in leukocytes. Science 344, 519-523 (2014).
53. Iwashyna, T. J., Ely, E. W ., Smith, D. M. & Langa, K. M. Long-term cognitive impairment and functional disability among survivors of severe sepsis. JAMA 304, 1787-1794 (2010).
54. Prinz, M. & Priller, J. Mi croglia and brain macrophages in the molecular age: from origin to neuropsychiatric disease. Nature Rev. Neurosci. 15, 300-312 (2014).
55. Du Yan, S. et al. Amyloid-? peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: a proinflammatory pathway in Alzheimer disease. Proc. Natl Acad. Sci. USA 94, 5296-5301 (1997).
56. El Khoury, J. et al. Scavenger receptor-mediated adhesion of microglia to ?-Amyloid fibrils. Nature 382, 716-719 (1996).
57. Bamberger, M. E., Harris, M. E., McDonald, D. R., Husemann, J. & Landreth, G. E. A cell surface receptor complex for fibrillar ?-Amyloid mediates microglial activation. J. Neurosci. 23, 2665-26 74 (2003).
58. Paresce, D. M., Ghosh, R. N. & Maxfield, F. R. Microglial cells internalize aggregates of the Alzheimer's disease amyloid ?-protein via a scavenger receptor. Neuron 17, 553-565 (1996).
59. Stewart, C. R. et al. CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nature Immunol. 11, 155-161 (2010).
60. Sheedy, F. J. et al. CD36 coordinates NLRP3 inflammasome activation by facilitating intracellular nucleation of soluble ligands into particulate ligands in sterile inflammation. Nature Immunol. 14, 812-820 (2013
61. Koenigsknecht, J. & Landreth, G. Microglial phagocytosis of fibrillar ?-Amyloid through a ?1 integrin-dependent mechanism. J. Neurosci. 24, 9838-9846 (2004).
62. Fassbender , K. et al. The LPS receptor (CD14) links innate immunity with Alzheimer's disease. FASEB J. 18, 203-205 (2004).
63. El Khoury, J. B. et al. CD36 mediates the innate host response to ?-Amyloid. J. Exp. Med. 197, 1657-1666 (2003).
64. Griffin, W. S. et al. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc. Natl Acad. Sci. USA 86, 7611-7615 (1989).
65. Patel, N. S. et al. Inflammatory cytokine levels correlate with amyloid load in transgenic mouse models of Alzheimer's disease. J. Neuroinflamm. 2, 9 (2005).
66. Vom Berg, J. et al. Inhibition of IL-12/IL-23 signaling reduces Alzheimer's disease-like pathology and cognitive decline. Nature Med. 18, 1812-1819 (2012).
67. Fillit, H. et al. Elevated circul ating tumor necrosis factor levels in Alzheimer's disease. Neurosci. Lett. 129, 318-320 (1991).
68. Tan, J. et al. Role of CD40 ligand in amyloidosis in transgenic Alzheimer's mice. Nature Neurosci. 5, 1288-1293 (2002).
69. Tan, J. et al. Microglial activation resulting from CD40-CD40L interaction after ?-Amyloid stimulation. Science 286, 2352-2355 (1999).
70. Jin, J. J., Kim, H. D., Maxwell, J. A., Li, L. & Fukuchi, K. Toll-like receptor 4-dependent upregulation of cytokines in a transgenic mouse model of Alzheimer's disease. J. Neuroinflamm. 5, 23 (2008).
71. Haass, C. & Selkoe, D. J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid ?-peptide. Nature Rev. Mol. Cell Biol. 8, 101-112 (2007).
72. Lee, C. Y. & Landreth, G. E. The role of microglia in amyloid clearance from the AD brain. J. Neural Transm. 117, 949-960 (2010).
73. Streit, W. J., Sammons, N. W., Kuhns, A. J. & Sparks, D. L. Dystrophic microglia in the aging human brain. Glia 45, 208-212 (2004).
74. Perry, V. H., Nicoll, J. A. & Holmes, C. Microglia in neurodegenerative disease. Nature Rev. Neurol. 6 , 193-201 (2010).
75. Krabbe, G. et al. Functional impairment of microglia coincides with beta-Amyloid deposition in mice with Alzheimer-like pathology. PLoS ONE 8, e60921 (2013).
76. Hickman S. E.,Allison E. K.,El Khoury J. Microglial dysfunction and defective ?-Amyloid clearance pathways in aging Alzheimer's disease mice J. Neurosci. 28 8354-8360 2008
77. Lucin K. M.,et al. Microglial beclin 1 regulates retromer trafficking and phagocytosis and is impaired in Alzheimer's disease Neuron 79, 873-886, 2013).
78. Mawuenyega, K. G. et al.Decreased clearance of CNS ?-Amyloid in Alzheimer's disease. Science 330, 1774 (2010).
79. Grathwohl, S. A. et al. Formation and maintenance of Alzheimer's disease ?-Amyloid plaques in the absenc e of microglia. Nature Neurosci. 12, 1361-1363 (2009).
80. Parkhurst, C. N. et al. Microglia promote learning-dependent synapse formation through brain-derived neurotrophic factor. Cell 155, 1596-1609 (2013).
81. Hong, S. et al. Soluble A? oligomers are rapidly sequestered from brain ISF in vivo and bind GM1 ganglioside on cellular membranes. Neuron 82, 308-319 (2014).
82. Selkoe, D. J. SnapShot: pathobiology of Alzheimer's disease. Cell 154, 468-468 e1 (2013).
83. Verdier, Y., Zarandi, M. & Penke, B. Amyloid ?-peptide interactions with neu ronal and glial cell plasma membrane: binding sites and implications for Alzheimer's disease. J. Pept. Sci. 10, 229-248 (2004).
84. Wake, H., Moorhouse, A.J. & Nabekura, J. Functions of microglia in the central nervous system-beyond the immune response. Neuron Glia Biol. 7, 47-53 (2011).
85. Salter, M. W. & Beggs, S. Sublime microglia: expanding roles for the guardians of the CNS. Cell 158, 15-24 (2014).
86. Frank, S. et al. TREM2 is upregulated in amy loid plaque-Associated microglia in aged APP23 transgenic mice. Glia 56, 1438-1447 (2008).
87. Hickman, S. E. et al. The microglial sensome revealed by direct RNA sequencing. Nature Neurosci. 1 6, 1896-1905 (2013).
88. Hsieh, C. L. et al. A role for TREM2 ligands in the phagocytosis of apoptotic neuronal cells by microglia. J. Neurochem. 109, 1144-1156 (2009).
89. Kleinberger G.,et al TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Sci. Transl Med. 6, 243ra86 2014).
90. Wang, Y. et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model. Cell 160, 1061-1071 (2015).
91. Jay, T. R. et al. TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pat hology in Alzheimer's disease mouse models. J. Exp. Med. 212, 287-295 (2015). These two publications show the importance and function of TREM2 in AD mouse models; that is, to promote the survival of activated microglia and myeloid ce lls, to recruit these cells to A? plaques through sensing for A?-Associated lipids, and to modulate hippocampal A? burden.
92. Ulrich, J. D. et al. Altered microglial response to A? plaques in APPPS1-21 mice heterozygous for TREM2. Mol. Neurodegener. 9, 20 (2014).
93. Lajaunias, F., Dayer, J. M. & Chizzolini, C. Constitutive repressor activity of CD33 on human monocytes requires sialic acid recognition and phosphoinosit ide 3-kinase-mediated intracellular signaling. Eur. J. Immunol. 35, 243-251 (2005).
94. Griciuc, A. et al. Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron 78, 631-643 (2013).
95. Miller, K. R. & Streit, W. J. The effects of aging, injury and disease on microglial function: a case for cellular senescence. Neuron Glia Biol. 3, 245-253 (2007).
96. El Khoury, J. et al. Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nature Med. 13, 432-438 (2007).
97. Hawkes, C. A. & McLaurin, J. Selective targeting of perivascular macrophages for clearance of ?-Amyloid in cerebral amyloid angiopathy. Proc. Natl Acad. Sci. USA 106, 1261-1266 (2009).
98. Hickey, W. F. & Kimur a, H. Perivascular microglial cells of the CNS are bone marrow-derived and present antigen in vivo. Science 239, 290-292 (1988).
99. Lai, A. Y. & McLaurin, J. Clearance of amyloid-? peptides by microglia and macrophages: the issue of what, when and where. Future Neurol. 7, 165-176 (2012).
100. Mildner, A.et al. Distinct and non-redundant roles of microglia and myeloid subsets in mouse models of Alzheimer's disease. J. Neurosci. 31, 11159-11171 (2011).
101. Gomez-Nicola, D., Schetters, S. T. & Perry, V. H. Differential role of CCR2 in the dynamics of microglia and perivascular macrophages during prion disease. Glia 62, 1041-1052 (2014).
102. Burda, J. E. & Sofroniew, M. V. Reactive gliosis and the multicellular response to CNS damage and disease. Neuron 81, 229-248 (2014).
103. Sofroniew, M. V. & Vinters, H. V. Astrocytes: biology and pathology. Acta Neuropathol. 119, 7-35 (2010).
104. Medeiros, R. & LaFerla, F. M. Astrocytes: conductors of the Alzheimer disease neuroinflammatory symphony. Exp. Neurol. 239, 133-138 (2013).
105. Heneka M. T.,et al. Focal glial activation coincides with increased BACE1 activation and precedes amyloid plaque deposition in APP[V717I] transgenic mice J. Neuroinflamm. 2 22, 2005).
106. Olabarria, M., Noristani, H. N., Verkhratsky, A. & Rodriguez, J. J. Age-dependent decrease in glutamine synthetase expression in the hippocampal astroglia of the triple transgenic Alzheimer's disease mouse model: mechanism for d eficient glutamatergic transmission? Mol. Neurodegener. 6, 55 (2011).
107. Olabarria, M., Noristani, H. N., Verkhratsky, A. & Rodriguez, J. J. Concomitant astroglial atrophy and astrogliosis in a triple transgenic animal model of Alzheimer's disease. Glia 58, 831-838 (2010).
108. Furman, J. L. et al. Targeting astrocytes ameliorates neurologic changes in a mouse model of Alzheimer's d isease. J. Neurosci. 32, 16129-16140 (2012).
109. Nagele, R. G., D'Andrea, M. R., Lee, H., Venkataraman, V. & Wang, H. Y. Astrocytes accumulate A?42 and give rise to astrocytic amy loid plaques in Alzheimer disease brains. Brain Res. 971, 197-209 (2003).
110. Wyss-Coray, T. et al. Adult mouse astrocytes degrade amyloid-? in vitro and in situ. Nature Med. 9, 453-457 (2003).
111. Koistinaho, M. et al. Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-? peptides. Nature Med. 10, 719-726 (2004).
112. Terwel, D. et al. Critical role of astroglial apolipoprotein E and liver X receptor-? expression for microglial A? phagocytosis. J. Neurosci. 31, 7049-7059 (2011).
113. Pihlaja R.,et al. Multiple cellular and molecular mechanisms are involved in human A? clearance by transplanted adult astrocytes Glia 59 1643-1657 2011)
114. Saido, T. & Leissring, M. A. Proteolytic degradation of amyloid ?-protein. Cold Spring Harb. Perspect. Med. 2, a006379 (2012).
115. Wyss-Coray, T. & Rogers, J. Inflammation in Alzheimer disease-A brief review of the basic science and clinical literature. Cold Spring Harb. Perspect. Med. 2, a006346 (2012).
116. Roth, A. D., Ramirez, G., Alarcon, R. & Von Bernhardi, R. Oligodendrocytes damage in Alzheimer's disease: beta amyloid toxicity and inflammation. Biol. Res. 38, 381-387 (2005).
117. Mitew, S. et al. Focal demyelination in Alzheimer's disease and transgenic mouse models. Acta Neuropathol. 119, 567-577 (2010).
118. Hosokawa, M., Klegeris, A., Maguire, J. & McGeer, P. L. Expression of complement messenger RNAs and proteins by human oligodendroglial cells. Glia 42, 417-4 23 (2003).
119. Yamada, T., Akiyama, H. & McGeer, P. L. Complement-Activated oligodendroglia: a new pathogenic entity identified by immunostaining with antibodies to human complement proteins C3d and C4d. Neurosc i. Lett. 112, 161-166 (1990).
120. Harrison, J. K. et al. Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia. Proc. Natl Acad. Sci. USA 95, 10896-10901 (1998).
121. Lee, S. et al. CX3CR1 deficiency alters microglial activation and reduces beta-Amyloid deposition in two Alzheimer's disease mouse models. Am. J. Pathol. 177, 2549-2562 (2010).
122. Singhrao, S. K., Muller, C. T., Gilbert, S. J., Duance, V. C. & Archer, C. W. An immunofluorescence method for postembedded tissue in the acrylic resin Technovit 9100 New using fluorescein isoth iocyanate secondary detection. Microsc. Res. Tech. 72, 501-506 (2009).
123. Yang, L. B., Li, R., Meri, S., Rogers, J. & Shen, Y. Deficiency of complement defense protein CD59 may contribute to neurodegeneration in Alzheimer's disease. J. Neurosci. 20, 7505-7509 (2000).
124. Walker, D. G., Dalsing-Hernandez, J. E., Campbell, N. A. & Lue, L. F. Decreased expression of CD200 and CD20 0 receptor in Alzheimer's disease: a potential mechanism leading to chronic inflammation. Exp. Neurol. 215, 5-19 (2009).
125. Sagare, A. P., Bell, R. D. & Zlokovic, B. V. Neurovascular dysfunction and faulty amyloid ?-peptide clearance in Alzheimer disease. Cold Spring Harb. Perspect. Med. 2, a011452 (2012).
126. Vukic, V. et al. Expression of inflammatory genes induced by beta-Amyloid peptides in human brain endothelial cells and in Alzheimer's brain is mediated by the JNK-AP1 signaling pathway. Neurobiol. Dis. 34, 95-106 (2009).
127. Palmer, J. C., Barker, R., Kehoe, P. G. & Love, S. Endothelin-1 is elevated in Alzheimer's disease and upregulated by amyloid-?. J. Alzheimers Dis. 29, 853-861 (2012).
128. Grammas P. Neurovascular dysfunction, inflammation and endothelial activation: implications for the pathogenesis of Alzheimer's disease J. Neuroinflamm. 8 26, 2011).
129. Lyros, E., Bakogia nnis, C., Liu, Y. & Fassbender, K. Molecular links between endothelial dysfunction and neurodegeneration in Alzheimer's disease. Curr. Alzheimer Res. 11, 18-26 (2014).
130. Chiang, K. & Koo, E. H. Emerging therapeutics for Alzheimer's disease. Annu. Rev. Pharmacol. Toxicol. 54, 381-405 (2014).
131. Michelucci, A., Heurtaux, T., Grandbarbe, L., Morga, E. & Heuschling, P. Characterization of the microglial phenotype under specific pro-inflammatory and anti-inflammatory conditions: effects of oligomeric and fibrillar amyloid-?. J. Neuroimmunol. 210, 3-12 (2009).
132. Martin ez, F. O. & Gordon, S. The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep. 6, 13 (2014).
133. Murray, P. J. et al. Macrophage activation and polarization : nomenclature and experimental guidelines. Immunity 41, 14-20 (2014).
134. Anand, P., Singh, B., Jaggi, A. S. & Singh, N. Mast cells: an expanding pathophysiological role from allergy to other disorders. Naunyn Schmiedebergs Arch. Pharmacol. 385, 657-670 (2012).
135. Piette, F. et al. Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-co ntrolled phase 2 trial. Alzheimers Res. Ther. 3, 16 (2011).
136. Breitner, J. C. & Zandi, P. P. Do nonsteroidal antiinflammatory drugs reduce the risk of Alzheimer's disease? N. Engl. J. Med. 345, 1567-1568 (2001).
137. in t' Veld, B. A. et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N. Engl. J. Med. 345, 1515-1521 (2001).
138. Aisen, P. S. The potential of anti-inflammatory drugs for the treatment of Alzheimer's disease. Lancet Neurol. 1, 279-284 (2002).
139. Group, A. R. et al. Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch. Neurol. 65, 896-905 (2008).
140. Group, A. R. et al. Naproxen and celecoxib do not preve nt AD in early results from a randomized controlled trial. Neurology 68, 1800-1808 (2007).
141. Aisen, P. S. et al. Effects of rofecoxib or naproxen versus placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 289, 2819-2826 (2003).
142. Breitner, J. C. et al. Extended results of the Alzheimer's disease anti-inflammatory prevention trial. Alzheimers Dement. 7, 402-411 (2011).
143. Lo, A. W., Ho, C., Cummings, J. & Kosik, K. S. Parallel discovery of Alzheimer's therapeutics. Sci. Transl Med. 6, 241cm5 (2014).
144. Guerreiro, R. J. et al. Peripheral inflammatory cytokines as biomarkers in Alzheimer's disease and mild cognitive impairment. Neurodegener. Dis. 4, 406-412 (2007).
145. Hu, W. T. et a l. Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Neurology 79, 897-905 (2012). Using an unbiased proteome approach, this study provides evidence for changes in immune-relevant factors in the plasma of MCI and AD patients.
146. Liu, Y. et al. Interleukin-23 receptor polymorphisms are associated with Alzheimer's disease in Han Chinese. J. Neuroimmunol. 271, 43-48 (2014).
147. Tan M. S.,et al. IL12/23 p40 inhibition ameliorates Alzheimer's disease-Associated neuropathology and spatial memory in SAMP8 mice J. Alzheimers Dis. 38 633-646, 2014).
148. Gr iffin, W. S. Neuroinflammatory cytokine signaling and Alzheimer's disease. N. Engl. J. Med. 368, 770-771 (2013).
149. Halle, A. et al. The NALP3 inflammasome is involved in the innate immune respo nse to amyloid-?. Nature Immunol. 9, 857-865 (2008).
150. Heneka, M. T. et al. NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature 493, 674-678 (2013).
151. Coll, R. C. et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nature Med. 21, 248-255 (2015).
152. Yamanaka, M. et al. PPAR?/RXR?-induced and CD36-mediated microglial amyloid-? phagocytosis results in cognitive improvement in amyloid precursor protein/presenilin 1 mice. J. Neurosci. 32, 17321-17331 (2012).
153. Cramer, P. E. et al. ApoE-directed therapeutics rapidly clear ?-Amyloid and reverse deficits in AD mouse models. Science 335, 1503-1506 (2012).
154. Veeraraghavalu, K. et al. Comment on "ApoE-directed therapeutics rapidly clear ?-Amyloid and reverse deficits in AD mouse models ". Science 340, 924-f (2013).
155. Tesseur, I. et al. Comment on "ApoE-directed therapeutics rapidly clear ?-Amyloid and reverse deficits in AD mouse models ". Science 340, 924-e (2013).
156. Price, A. R. et al. Comment on "ApoE-directed therapeutics rapidly clear ?-Amyloid and reverse deficits in AD mouse models ". Science 340, 924-d (2013).
157. Fitz, N. F., Cronican, A. A., Lefterov, I. & Koldamova, R. Comment on "ApoE-directed therapeutics rapidly clear ?-Amyloid and reverse deficits in AD mouse models".Science 340, 924-c (2013).
158. Fuhrmann, M. et al. Microglial Cx3cr1 knockout prevents neuron loss in a mouse model of Alzheimer's disease. Nature Neurosci. 13, 411-413 (2010).
159. Nash, K. R. et al. Fractalkine overexpression suppresses tau pathology in a mouse model of tauopathy. Neurobiol. Aging 34, 1540-1548 (2013).
160. Frenkel, D. et al. Scara1 deficiency impairs clearance of soluble amyloid-? by mononuclear phagocytes and accelerates Alzheimer's-like disease progression. Nature Commun. 4, 2030 (2013).
161. Wyss-Coray , T. et al. Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice. Proc. Natl Acad. Sci. USA 99, 10837-10842 (2002).
162. Fonseca, M. I., Zhou, J., Botto, M. & Tenner, A. J. Absence of C1q leads to less neuropathology in transgenic mouse models of Alzheimer's disease. J. Neurosci. 24, 6457-6465 (2004).
163. Maier, M. et al. Complement C3 defi ciency leads to accelerated amyloid ? plaque deposition and neurodegeneration and modulation of the microglia/macrophage phenotype in amyloid precursor protein transgenic mice. J. Neurosci. 28, 6333-6341 (2008).
164. Paolicelli, R. C. et al. Synaptic pruning by microglia is necessary for normal brain development. Science 333, 1456-1458 (2011).
165. Schafer, D. P. et al. Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. Neuron 74, 691-705 (2012).
166. Stephan, A. H., Barres, B. A. & Stevens, B. The complement system: an unexpected role in synaptic pruning during development and disease. Annu. Rev. Neurosci. 35, 369-389 (2012).
167. van der Wal E. A.,Gómez-Pinilla, F.,Cotman, C. W. Transforming growth factor-beta 1 is in plaques in Alzheimer and Down pathologies Neuroreport 4 69-72, 1993).
168. Wyss-Coray, T. et al. TGF-?1 promotes microglial amyloid-? clearance and reduces plaque burden in transgenic mice. Nature Med. 7, 612-618 (2001).
169. 69. Town, T. et al. Blocking TGF-?-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology. Nature Med. 14, 681-687 (2008).
170. Swardfager, W. et al. A meta-Analysis of cytokines in Alzheimer's disease. Biol. Psychiatry 68, 930-941 (2010).
171. Simard, A. R., Soulet, D., Gowing, G., Julien, J. P. & Rivest, S. Bone marrow-derived microglia play a critical r ole in restricting senile plaque formation in Alzheimer's disease. Neuron 49, 489-502 (2006).
172. Bard, F. et al. Peripherally administered antibodies against amyloid ?-peptide enter the central nervous system and reduce pathology in a mouse model of alzheimer disease. Nature Med. 6, 916-919 (2000).
173. Garcia-Alloza, M. et al. A limited role for microglia in antibody mediated plaque clearance in APP mice. Neurobiol. Dis. 28, 286-292 (2007).
174. Golde, T. E., Das, P. & Levites, Y. Quantitative and mechanistic studies of A? immunotherapy. CNS Neurol. Disord. Drug Targets 8, 31-49 (2009).
175. Koenigsknecht-Talboo, J. et al. Rapid microglial response around amyloid pathology after systemic anti-Abeta antibody administration in PDAPP mice. J. Neurosci. 28, 14156-14164 (2008).
176. Wilcock, D. M. et al. Intracranially administered anti-A? antibodies reduce ?-Amyloid deposition by mechanisms both independent of and associated with microglial activation. J. Neurosci. 23, 3745-3751 (20 03).
177. Wilcock, D. M. et al. Microglial activation facilitates A? plaque removal following intracranial anti-A? antibody administration. Neurobiol. Dis. 15, 11-20 (2004).
178. Wilcoc k, D. M. et al. Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J. Neurosci. 24, 6144-6151 (2004).
179. Wang, A., D as, P., Switzer, R. C. 3rd, Golde, T. E. & Jankowsky, J. L. Robust amyloid clearance in a mouse model of Alzheimer's disease provides novel insights into the mechanism of amyloid-? immunotherapy. J. Neurosci. 31, 4124-4136 (2011).
180. Citron, M. Alzheimer's disease: strategies for disease modification. Nature Rev. Drug Discov. 9, 387-398 (2010).
181. Medeiros, R. et al. Aspiri n-triggered lipoxin A4 stimulates alternative activation of microglia and reduces Alzheimer disease-like pathology in mice. Am. J. Pathol. 182, 1780-1789 (2013).
182. Kiyota, T. et al. AAV serotype 2/1-mediated gene delivery of anti-inflammatory interleukin-10 enhances neurogenesis and cognitive function in APP+PS1 mice. Gene Ther. 19, 724-733 (2012).
183. Chakrabarty, P. et al. IL-10 alters immunoproteostasis in APP mice, increasing plaque burden and worsening cognitive behavior. Neuron 85, 519-533 (2015).
184. Jin, P. et a l. Anti-inflammatory and anti-Amyloidogenic effects of a small molecule, 2,4-bis(p-hydroxyphenyl)-2-butenal in Tg2576 Alzheimer's disease mice model. J. Neuroinflamm. 10, 2 (2013).
185. Chakrabarty, P. et al.Hippocampal expression of murine IL-4 results in exacerbation of amyloid deposition. Mol. Neurodegener. 7, 36 (2012).
186. Imbimbo, B. P. et al. CHF5074, a novel ?-secretase modulator, attenuates brai n ?-Amyloid pathology and learning deficit in a mouse model of Alzheimer's disease. Br. J. Pharmacol. 156, 982-993 (2009).
187. Sivilia, S. et al. Multi-target action of the novel anti-Alzheimer compound CHF5 074: in vivo study of long term treatment in Tg2576 mice. BMC Neurosci. 14, 44 (2013).
188. CERESPIR. CERESPIR Incorporated is pleased with positive interim Phase 2 results for CHF 5074 in patients with mild co gnitive impairment, presented by Chiesi at the AAIC 2013 Meeting in Boston. CERESPIR [online], http://www.cerespir.com/cerespir-incorporated-is-pleased-with-positive-interim-phase-2-results-for-chf-5074-in-patients-with-mild-cognitive-impairment-pres ented-by-chiesi-At-the-Aaic-2013-meeting-in-boston/(2013).
189. Ross, J. et al. CHF5074 reduces biomarkers of neuroinflammation in patients with mild cognitive impairment: a 12-week, double-blind, placebo-controlled stud y. Curr. Alzheimer Res. 10, 742-753 (2013).
190. Villeda, S. A. et al. The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature 477, 90-94 (2011).
191. Villeda, S. A. et al. Young blood reverses age-related impairments in cognitive function and synaptic plasticity in mice. Nature Med. 20, 659-663 (2014). These two studies show that changes in blood-borne factors including immune molecules such as the chemokine CCL11 are linked to impaired neurogenesis and decline in cognitive performance during ageing, which can be rescued by transfer of young blood to aged mice.
192. Mackaness, G. B. Cellular resistance to infection. J. Exp. Med. 116, 381-406 (1962).
193. Nathan, C. F., Murray, H. W., Wiebe, M. E. & Rubin, B. Y. Identification of interferon-? as t he lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J. Exp. Med. 158, 670-689 (1983).
194. Stein, M., Keshav, S., Harris, N. & Gordon, S. Interleukin 4 p otently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J. Exp. Med. 176, 287-292 (1992).
195. Mosmann, T. R., Cherwinski, H., Bond, M. W., Giedlin, M. A. & Coffman, R. L. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J. Immunol. 136, 2348-2357 (1986).
196. Mi lls, C. D., Kincaid, K., Alt, J. M., Heilman, M. J. & Hill, A. M. M-1/M-2 macrophages and the Th1/Th2 paradigm. J. Immunol. 164, 6166-6173 (2000).
197. Vahedi, G., Kanno, Y., Sartorelli, V. & O'Shea, J. J. Transcription factors and CD4 T cells seeking identity: masters, minions, setters and spikers. Immunology 139, 294-298 (2013).
198. Hirahara, K. et al. Helper T-cell differentiation and plasticity: insights from epigenetics. Immunology 134, 235-245 (2011).
199. Josefowicz, S. Z. Regulators of chroma tin state and transcription in CD4 T-cell polarization. Immunology 139, 299-308 (2013).
200. Lawrence, T. & Natoli, G. Transcriptional regulation of macrophage polarization: enabling diversity with identity. Nature Rev. Immunol. 11, 750-761 (2011).
201. Lacey, D. C. et al. Defining GM-CSF-And macrophage-CSF-dependent macrophage responses by in vitro models. J. Immunol. 188, 5752-5765 (2012).
202. Xue, J. et al. Transcriptome-based network analysis reveals a spectrum model of human macrophage activation. Immunity 40, 274-288 (2014).
203. Chiu, I. M. et al. A neurodegeneration-specific gene-expression signature of acutely isolated microglia from an amyotrophic lateral sclerosis mouse model. Cell Rep. 4, 385-401 (2013).
204. Mu cke, L. & Selkoe, D. J. Neurotoxicity of amyloid ?-protein: synaptic and network dysfunction. Cold Spring Harb. Perspect. Med. 2, a006338 (2012).
205. Cui, Y. H. et al. Up-regulation of FPR2, a chemo tactic receptor for amyloid ? 1-42 (A?42), in murine microglial cells by TNF?. Neurobiol. Dis. 10, 366-377 (2002).
206. Lotz, M. et al. Amyloid beta peptide 1-40 enhances the action of Toll-like receptor-2 an d-4 agonists but antagonizes Toll-like receptor-9-induced inflammation in primary mouse microglial cell cultures. J. Neurochem. 94, 289-298 (2005).
207. Reed-Geaghan, E. G., Savage, J. C., Hise, A. G. & Landreth, G. E. CD14 and Toll-like receptors 2 and 4 are required for fibrillar A?-stimulated microglial activation. J. Neurosci. 29, 11982-11992 (2009).
208. Hu, J., Akama, K. T., Krafft, G. A., Chromy, B. A. & Van Eldik, L. J. Amyloid-? peptide activates cultured astrocytes: morphological alterations, cytokine induction and nitric oxide release. Brain Res. 785, 195-206 (1998).
209. Larson, M. et al. The complex PrPc-Fyn couples human oligomeric A? with pathological tau changes in Alzheimer's disease. J. Neurosci. 32, 16857-71a (2012).
210. Papassotiropoulos, A. et al. A geneti c variation of the inflammatory cytokine interleukin-6 delays the initial onset and reduces the risk for sporadic Alzheimer's disease. Ann. Neurol. 45, 666-668 (1999).
211. Chakrabarty, P. et al. Massive gliosis induced by interleukin-6 suppresses A? deposition in vivo: evidence against inflammation as a driving force for amyloid deposition. FASEB J. 24, 548-559 (2010).
212. Chakrabarty, P., Herring, A., Ceballos-Diaz, C., Das, P. & Golde, T. E. Hippocampal expression of murine TNF? results in attenuation of amyloid deposition in vivo. Mol. Neurodegener. 6, 16 (2011).
213. Li, R. et al. Tumor necrosis factor death receptor signaling cascade is required for amyloid-? protein-induced neuron death. J. Neurosci. 24, 1760-1771 (2004).
214. Cheng, X., Yang, L., He, P., Li, R. & Shen, Y. Differential activation of tumor necrosis factor receptors distinguishes between brains from Alzheimer's disease and non-demented patients. J. Alzheimers Dis. 19, 62 1-630 (2010).
215. Tobinick, E. L. & Gross, H. Rapid cognitive improvement in Alzheimer's disease following perispinal etanercept administration. J. Neuroinflamm. 5, 2 (2008).
216. Ryu J. K.,McLarnon J. G. Block of purinergic P2X7 receptor is neuroprotective in an animal model of Alzheimer's disease Neuroreport 19 1715-1719, 2008)
217. Diaz-Hernandez, J. I. et al. In vivo P2X7 inhibition reduces amyloid plaques in Alzheimer's disease through GSK3? and secretases. Neurobiol. Aging 33, 1816-1828 (2012).